Cost Of Services - Molecular Profiling Services was Caris Life Sciences’s largest product and service line in fiscal 2025, bringing in $766.72M of $812.03M (94%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Cost Of Services - Molecular Profiling Services | $278.75M | $349.12M | $766.72M |
| Cost Of Services - Pharma Research & Development Services | $27.38M | $63.15M | $45.31M |
| Total | $306.13M | $412.26M | $812.03M |
Caris Life Sciences brought in $812.03M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 97.0% from $412.26M in fiscal 2024. Cost Of Services - Molecular Profiling Services was the largest at $766.72M (94.4%), ahead of Cost Of Services - Pharma Research & Development Services at $45.31M (5.6%).
Compared with fiscal 2024, Cost Of Services - Molecular Profiling Services grew 119.6% to $766.72M, while Cost Of Services - Pharma Research & Development Services fell 28.2% to $45.31M. From fiscal 2023 to 2025, combined revenue from these lines grew from $306.13M to $812.03M, a compound annual growth rate of 62.9%. Cost Of Services - Molecular Profiling Services' share of the total rose from 91.1% to 94.4%.
United States was Caris Life Sciences’s largest region in fiscal 2025, bringing in $801.39M of $812.03M (99%).
| Geography | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| United States | $293.41M | $401.84M | $801.39M |
| International | $12.72M | $10.42M | $10.64M |
| Total | $306.13M | $412.26M | $812.03M |
Caris Life Sciences brought in $812.03M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 97.0% from $412.26M in fiscal 2024. United States was the largest at $801.39M (98.7%), ahead of International at $10.64M (1.3%).
From fiscal 2023 to 2025, combined revenue from these regions grew from $306.13M to $812.03M, a compound annual growth rate of 62.9%. United States' share of the total rose from 95.8% to 98.7%.
Caris Life Sciences (CAI) reports its revenue by product and service and by geography. In fiscal 2025, Cost Of Services - Molecular Profiling Services was its largest product and service line, bringing in $766.72M (94.4% of the total), followed by Cost Of Services - Pharma Research & Development Services at $45.31M (5.6%).
Cost Of Services - Molecular Profiling Services was Caris Life Sciences' largest product and service line in fiscal 2025, bringing in $766.72M, or 94.4% of the $812.03M total across its two product and service lines.
United States was Caris Life Sciences' largest region in fiscal 2025, bringing in $801.39M, or 98.7% of the $812.03M total across its two regions.
Cost Of Services - Molecular Profiling Services grew faster than Cost Of Services - Pharma Research & Development Services in fiscal 2025, up 119.6% from $349.12M to $766.72M. Cost Of Services - Pharma Research & Development Services fell 28.2% to $45.31M.
Every figure comes from Caris Life Sciences' annual financial filings, as reported. Each line keeps the name Caris Life Sciences gives it, and years follow its fiscal calendar.
Caris Life Sciences' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.